Bioeq announces Coherus as marketing and distribution partner for its biosimilar to Lucentis® (ranibizumab) in the U.S.
- Bioeq agreement brings promise of their leading Lucentis® biosimilar for the treatment of retinopathies one step nearer for U.S. patients -
Zürich, Switzerland. Bioeq IP AG (“Bioeq”) has announced that it signed a license and development agreement with Coherus BioSciences, Inc. (“Coherus” Nasdaq:CHRS), under which Coherus will exclusively market and distribute Bioeq’s biosimilar candidate to Lucentis® (ranibizumab) in the United States (U.S.).
Bioeq will retain responsibility for filing of the Biologics License Application (BLA) with the U.S. Food and Drug Administration in Q4 2019 and for subsequent product supply. Coherus plans to launch the product in 2021.
Commenting on the agreement, Hannes Teissl, Board Member at Bioeq, said, “We are proud of having secured Coherus as our partner of choice for the U.S. This agreement is an important milestone in bringing a more affordable, highly effective treatment option for retinopathies, including age-related macular degeneration, to U.S. patients.”
According to the terms of the agreement, Bioeq will receive upfront, regulatory and launch milestone payments as well as shared profits.
Commenting on future plans, Nicola Mikulcik, Board Member at Bioeq, said, “Starting in 2020, Bioeq will also be in a position to offer rights for its biosimilar ranibizumab to marketing and distribution partners outside the U.S.”